Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses the controversy surrounding prostate-specific antigen (PSA) testing in prostate cancer.

The United States Preventative Services Task Force gave PSA testing a grade ‘D’ recommendation in 2012 based on evidence regarding both the benefits and harms of the service and an assessment of the balance.

Since the D grade was announced a lot less screening has been conducted, says Mehlhaff, especially in men in their 50s or 60s. Mehlhaff believes this has lead to delayed diagnosis of prostate cancers and more men being diagnosed with advanced stage, hormone-sensitive prostate cancer.

Videos

​Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses the controversy surrounding prostate-specific antigen (PSA) testing in prostate cancer.

Dr. Bryan Mehlhaff on PSA's Role in Prostate Cancer

Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses recent advancements in and what he sees on the horizon for metastatic castrate-resistant prostate cancer (mCRPC).

Sipuleucel-T (Provenge), abiraterone acetate (Zytiga), enzalutamide (Xtandi), and radium-223 have all made a significant impact in mCRPC in recent years, says Mehlhaff.

There has been a lot of progress in mCRPC. Six to 8 years ago urologists could only give hormone therapy or used the first generation receptor blockers; there really wasn’t a lot to offer.

Today we’ve doubled the life expectancy of mCRPC, and those are quality added years, not just life extension, says Mehlhaff. There are more advances on the horizon and patients with mCRPC have a better outlook than ever before, he adds

Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses recent advancements in and what he sees on the horizon for metastatic castrate-resistant prostate cancer (mCRPC).
 

Bryan Mehlhaff, MD

Articles

Dr. Bryan Mehlhaff on PSA's Role in Prostate Cancer

Dr. Bryan Mehlhaff on Advances in mCRPC